Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.88 |
| ▸ | CDK8 | P49336 | 2/20 | 0.88 |
| ▸ | CDK1 | P06493 | 1/20 | 0.88 |
| ▸ | ABL1 | P00519 | 8/20 | 0.69 |
| ▸ | SRC | P12931 | 6/20 | 0.69 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.69 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.69 |
| ▸ | KDR | P35968 | 4/20 | 0.69 |
| ▸ | RET | P07949 | 4/20 | 0.69 |
| ▸ | BCR | P11274 | 3/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.69 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.69 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.69 |
| ▸ | TEK | Q02763 | 2/20 | 0.69 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.69 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.69 |
| ▸ | STK25 | O00506 | 1/20 | 0.69 |
| ▸ | CIT | O14578 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678397 | 1.00 | CDK2 (0.88) | CDK2CDK8CDK1ABL1SRC | |
| SCHEMBL3676641 | 0.93 | CDK2 (1.00) | CDK2CDK8CDK1ABL1SRC | |
| SCHEMBL29678277 | 0.93 | CDK2 (1.00) | CDK2CDK8CDK1ABL1SRC | |
| SCHEMBL4937809 | 0.92 | CDK2 (0.85) | CDK2CDK8CDK1ABL1SRC | |
| SCHEMBL4931472 | 0.91 | CDK2 (0.84) | CDK2CDK8CDK1ABL1SRC | |
| SCHEMBL13991160 | 0.90 | CDK2 (0.82) | CDK2CDK8CDK1ABL1SRC | |
| SCHEMBL4762420 | 0.86 | SRC (0.81) | CDK2CDK8CDK1ABL1SRC | |
| SCHEMBL4936336 | 0.85 | CDK2 (0.74) | CDK2CDK8CDK1ABL1SRC | |
| SCHEMBL4936685 | 0.84 | CDK8 (0.82) | CDK2CDK8CDK1ABL1SRC | |
| SCHEMBL3183607 | 0.83 | SRC (0.82) | CDK2CDK8CDK1ABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338168-A1 | Combinations of JAK Inhibitors | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | claimed |
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | COOKE NIGEL GRAHAM | 2010-11-04 | — | — | US | claimed |
| US-20090156602-A1 | Organic Compounds | COOKE NIGEL GRAHAM | 2009-06-18 | — | — | US | claimed |
| US-20080207591-A1 | Organic Compounds | MANLEY PAUL W | 2008-08-28 | — | — | US | claimed |
| EP-1954278-A2 | COMBINATION COMPRISING A PYRIMIDYLAMINOBENZAMIDES AND A FLT-3 INHIBITOR FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2008-08-13 | — | — | EP | claimed |
| EP-1885352-A2 | COMBINATIONS COMPRISING JAK INHIBITORS AND AT LEAST ONE OF BCR-ABL, FLT-3, FAK OR RAF KINASE INHIBITORS | Novartis AG (US) | 2008-02-13 | — | — | EP | claimed |
| WO-2007010013-A2 | COMBINATION COMPRISING A PYRIMIDYLAMINOBENZAMIDES AND A FLT-3 INHIBITOR FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | claimed |
| WO-2006056399-A2 | COMBINATIONS OF JAK INHIBITORS AND AT LEAST ONE OF BCR-ABL, FLT-3, FAK OR RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-06-01 | — | — | WO | claimed |
| US-20130338168-A1 | Combinations of JAK Inhibitors | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | COOKE NIGEL GRAHAM | 2010-11-04 | — | — | US | disclosed |
| US-20090156602-A1 | Organic Compounds | COOKE NIGEL GRAHAM | 2009-06-18 | — | — | US | disclosed |
| US-20080207591-A1 | Organic Compounds | MANLEY PAUL W | 2008-08-28 | — | — | US | disclosed |
| EP-1954278-A2 | COMBINATION COMPRISING A PYRIMIDYLAMINOBENZAMIDES AND A FLT-3 INHIBITOR FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2008-08-13 | — | — | EP | disclosed |
| EP-1885352-A2 | COMBINATIONS COMPRISING JAK INHIBITORS AND AT LEAST ONE OF BCR-ABL, FLT-3, FAK OR RAF KINASE INHIBITORS | Novartis AG (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007010013-A2 | COMBINATION COMPRISING A PYRIMIDYLAMINOBENZAMIDES AND A FLT-3 INHIBITOR FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006056399-A2 | COMBINATIONS OF JAK INHIBITORS AND AT LEAST ONE OF BCR-ABL, FLT-3, FAK OR RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | JAK2, JAK3, JAK1 | CDK2 308/4885CDK8 651/4885CDK1 401/4885 |
| US-20130338168-A1 | Combinations of JAK Inhibitors | JAK2, JAK3, JAK1 | CDK2 308/4885CDK8 651/4885CDK1 401/4885 |
| US-20080207591-A1 | Organic Compounds | FLT4, FLT1, FLT3 | CDK2 34/4885CDK8 116/4885CDK1 77/4885 |
| US-20090156602-A1 | Organic Compounds | BTK, JAK2, JAK3 | CDK2 158/4885CDK8 364/4885CDK1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.